JP2024527542A5 - - Google Patents
Info
- Publication number
- JP2024527542A5 JP2024527542A5 JP2023580484A JP2023580484A JP2024527542A5 JP 2024527542 A5 JP2024527542 A5 JP 2024527542A5 JP 2023580484 A JP2023580484 A JP 2023580484A JP 2023580484 A JP2023580484 A JP 2023580484A JP 2024527542 A5 JP2024527542 A5 JP 2024527542A5
- Authority
- JP
- Japan
- Prior art keywords
- stabilizer
- sulfonyl
- modified oligonucleotide
- nucleoside
- oxidizing agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163217137P | 2021-06-30 | 2021-06-30 | |
| US63/217,137 | 2021-06-30 | ||
| PCT/US2022/035539 WO2023278589A1 (en) | 2021-06-30 | 2022-06-29 | Method for synthesis of linkage modified oligomeric compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527542A JP2024527542A (ja) | 2024-07-25 |
| JP2024527542A5 true JP2024527542A5 (https=) | 2025-07-08 |
Family
ID=84691597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023580484A Pending JP2024527542A (ja) | 2021-06-30 | 2022-06-29 | 結合修飾オリゴマー化合物の合成のための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240287520A1 (https=) |
| EP (1) | EP4363572A4 (https=) |
| JP (1) | JP2024527542A (https=) |
| KR (1) | KR20240027745A (https=) |
| CN (1) | CN117480254A (https=) |
| WO (1) | WO2023278589A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20220062517A (ko) | 2019-08-15 | 2022-05-17 | 아이오니스 파마수티컬즈, 인코포레이티드 | 결합 변형된 올리고머 화합물 및 이의 용도 |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| EP4689110A1 (en) | 2023-03-24 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| EP4688143A1 (en) | 2023-03-27 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2024220934A1 (en) | 2023-04-21 | 2024-10-24 | University Of Rochester | Nucleic acid molecules for pseudouridylation |
| TW202516003A (zh) | 2023-06-16 | 2025-04-16 | 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ | 用於治療神經退化性疾病之反義寡核苷酸 |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025072713A1 (en) | 2023-09-27 | 2025-04-03 | Judo Bio, Inc. | Polymyxins for delivery of agents to the kidney |
| WO2025072672A2 (en) | 2023-09-27 | 2025-04-03 | Judo Bio, Inc. | Slc6a19-targeting modulatory nucleic acid agents |
| WO2025072699A1 (en) | 2023-09-27 | 2025-04-03 | Judo Bio, Inc. | Aminoglycosides for delivery of agents to the kidney |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| WO2025141016A1 (en) * | 2023-12-27 | 2025-07-03 | F. Hoffmann-La Roche Ag | A method for the synthesis of oligonucleotides with modfied internucleoside linkages |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| GB202405143D0 (en) | 2024-04-11 | 2024-05-29 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of poly-q disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| WO2025240884A1 (en) * | 2024-05-17 | 2025-11-20 | Ionis Pharmaceuticals, Inc. | Patterned modified oligonucleotides |
| WO2025250953A1 (en) * | 2024-05-31 | 2025-12-04 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric agents and uses thereof |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
| WO2026080897A1 (en) | 2024-10-11 | 2026-04-16 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of chronic pain |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2740501C2 (ru) * | 2017-02-21 | 2021-01-14 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | МОДИФИЦИРОВАННЫЕ ОЛИГОНУКЛЕОТИДЫ, АКТИВИРУЮЩИЕ РНКазу Н |
| KR20220062517A (ko) * | 2019-08-15 | 2022-05-17 | 아이오니스 파마수티컬즈, 인코포레이티드 | 결합 변형된 올리고머 화합물 및 이의 용도 |
-
2022
- 2022-06-29 CN CN202280041577.XA patent/CN117480254A/zh active Pending
- 2022-06-29 WO PCT/US2022/035539 patent/WO2023278589A1/en not_active Ceased
- 2022-06-29 EP EP22834149.1A patent/EP4363572A4/en active Pending
- 2022-06-29 KR KR1020247002976A patent/KR20240027745A/ko active Pending
- 2022-06-29 JP JP2023580484A patent/JP2024527542A/ja active Pending
- 2022-06-29 US US18/571,631 patent/US20240287520A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024527542A5 (https=) | ||
| AU739468B2 (en) | Activators for oligonucleotide synthesis | |
| EP2277886B1 (en) | The use of n-alkyl imidazole for sulfurization of oligonucleotides with an acetyl disulfide | |
| US6630581B2 (en) | Monomers for solid phase synthesis of oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection | |
| JP3170241B2 (ja) | ヌクレオチド試薬 | |
| EP2599785A1 (en) | Novel methods for the synthesis and purification of oligomers | |
| US20100331533A1 (en) | Use Of Thioacetic Acid Derivatives In The Sulfurization Of Oligonucleotides With Phenylacetyl Disulfide | |
| JPS6250479B2 (https=) | ||
| WO1997019092A1 (en) | Improved process for the synthesis of oligomeric compounds | |
| WO2002020537A2 (en) | Linker phosphoramidites for oligonucleotide synthesis | |
| JP2004508379A (ja) | オリゴヌクレオチド合成用のシントン | |
| EP3154996A2 (en) | Protecting groups for "z nucleotide" and methods thereof | |
| EP3818066B1 (en) | Double coupling method for oligonucleotide synthesis | |
| Tsukamoto et al. | Strategies useful for the chemical synthesis of oligonucleotides and related compounds | |
| CA2078256A1 (en) | Synthesis of sulfide-linked di-or oligonucleotide analogs and incorporation into antisense dna or rna | |
| EP1828218B1 (en) | Synthesis of phosphitylated compounds using a quaternary heterocyclic activator | |
| CN115315430A (zh) | 使用了链段型亚磷酰胺化合物的核酸合成法 | |
| PL170146B1 (pl) | Sposób wykrywania obecnosci danej sekwencji oligonukleotydowej PL | |
| HK1000191B (en) | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use | |
| HK1000191A1 (en) | Modified oligodeoxyribonucleotides, their preparation and their therapeutic use |